Literature DB >> 11413369

Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats.

Regina Hofmann-Lehmann1, Jon B Huder1, Sabine Gruber1, Felicitas Boretti1, Brigitte Sigrist1, Hans Lutz1.   

Abstract

Feline leukaemia virus (FeLV) infection in domestic cats can vary in its outcome (persistent, transient, no infection) for reasons that are not entirely known. It was hypothesized that the initial virus and provirus load could significantly influence the course of retrovirus infection. To determine the role of provirus loads, two methods of PCR, a nested PCR and a fluorogenic probe-based (TaqMan) real-time quantitative PCR, which were specific to the U3 region of FeLV-A were established. FeLV provirus in naturally and experimentally infected cats was then measured. Only 3 weeks after experimental FeLV-A infection, persistently infected cats demonstrated higher provirus loads and lower humoral immune responses than cats that had overcome antigenaemia. Lower initial provirus loads were associated with successful humoral immune responses. Unexpectedly, provirus in the buffy-coat cells of two cats that tested negative for the p27 antigen (a marker for viraemia) was also detected. In 597 Swiss cats, comparison of p27 antigen levels with PCR results revealed broad agreement. However, similar to the experimental situation, a significant number of animals (10%) was negative for the p27 antigen and FeLV-positive by PCR. These cats had a mean provirus load 300-fold lower than that of animals testing positive for the p27 antigen. In conclusion, an association between the provirus load and the outcome of FeLV infection was found. Detection of provirus carriers should contribute to further the control of FeLV. In addition, quantification of provirus loads will lead to a better understanding of FeLV pathogenesis and anti-retrovirus protective mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413369     DOI: 10.1099/0022-1317-82-7-1589

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.

Authors:  Hervé Poulet; Jean-Christophe Thibault; Alonso Masias
Journal:  Clin Vaccine Immunol       Date:  2015-12

2.  Molecular Detection of Feline Leukemia Virus in Oral, Conjunctival, and Rectal Mucosae Provides Results Comparable to Detection in Blood.

Authors:  Raphael Mattoso Victor; Juliana Marques Bicalho; Manuela Bamberg Andrade; Bruna Lopes Bueno; Luiza Rodrigues Alves de Abreu; Adriane Pimenta da Costa Val Bicalho; Jenner Karlisson Pimenta Dos Reis
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

3.  Identification, molecular characterization, and experimental transmission of a new hemoplasma isolate from a cat with hemolytic anemia in Switzerland.

Authors:  Barbara Willi; Felicitas S Boretti; Valentino Cattori; Séverine Tasker; Marina L Meli; Claudia Reusch; Hans Lutz; Regina Hofmann-Lehmann
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

5.  Seroprevalences to viral pathogens in free-ranging and captive cheetahs (Acinonyx jubatus) on Namibian Farmland.

Authors:  Susanne Thalwitzer; Bettina Wachter; Nadia Robert; Gudrun Wibbelt; Thomas Müller; Johann Lonzer; Marina L Meli; Gert Bay; Heribert Hofer; Hans Lutz
Journal:  Clin Vaccine Immunol       Date:  2009-12-02

6.  Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma.

Authors:  A Katrin Helfer-Hungerbuehler; Valentino Cattori; Felicitas S Boretti; Pete Ossent; Paula Grest; Manfred Reinacher; Manfred Henrich; Eva Bauer; Kim Bauer-Pham; Eva Niederer; Edgar Holznagel; Hans Lutz; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2010-02-19       Impact factor: 4.602

7.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

8.  Epizootiology and management of feline leukemia virus in the Florida puma.

Authors:  Mark W Cunningham; Meredith A Brown; David B Shindle; Scott P Terrell; Kathleen A Hayes; Bambi C Ferree; R T McBride; Emmett L Blankenship; Deborah Jansen; Scott B Citino; Melody E Roelke; Richard A Kiltie; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Wildl Dis       Date:  2008-07       Impact factor: 1.535

9.  Detection of feline leukemia virus RNA in saliva from naturally infected cats and correlation of PCR results with those of current diagnostic methods.

Authors:  M A Gomes-Keller; E Gönczi; R Tandon; F Riondato; R Hofmann-Lehmann; M L Meli; H Lutz
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection.

Authors:  Andrea Major; Valentino Cattori; Eva Boenzli; Barbara Riond; Peter Ossent; Marina Luisa Meli; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2009-10-28       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.